摘要
目的:检出恩替卡韦(ETV)治疗失败的慢性乙型肝炎(CHB)患者的耐药.方法:收集ETV治疗失败的患者血清20份,根据应答情况分为非完全病毒学应答组和病毒学突破组.PCR产物直接测序法检测ETV耐药,NCBI HBV基因型分析软件确定HBV基因型.结果:20例患者中,检出ETV耐药11例,其变异类型以rtM204V+rtL180M+rtT184L为主.非完全病毒学应答组6例患者中未检出ETV耐药,病毒学突破组14例患者中检出ETV耐药11例,二者之间有统计学差异(P=0.0022).B基因型6例患者中检出ETV耐药3例,C基因型14例患者中检出ETV耐药8例,二者之间无统计学差异.结论:rtM204V+rtL180M+rtT184L变异类型在B和C基因型的ETV耐药患者中较为常见;ETV耐药多见于病毒学突破患者;ETV治疗失败患者的耐药检出率在B和C基因型中无显著差异.
AIM： To investigate the resistance profiles of chronic hepatitis B patients with entecavir （ETV） refractory treatment.
METHODS： Twenty serum samples of patients who failed treatment with ETV were assigned into non-complete virological group and virological breakthrough group in accordance with response action. Direct sequencing of PCR products was used to determine ETV resistance. NCBI HBV genotyping tool was used to identify HBV genotype.
RESULTS： ETV resistance was detected from 11 out of 20 ETV-refractory patients, all of which was in virological breakthrough group, and rtM204V ＋ rtL180M ＋ rtT184L was common in Chinese ETV resistance patients. There was remarkably statistical difference between the two groups （P = 0.0022）. Three in 6 patients with genotype B were detected to have ETV resistance, meanwhile 11 in 14 with genotype C. There was no statistical difference in resistance among genotype B and C patients.
CONCLUSION： rtM204V ＋ rtL180M ＋ rtT184L mutations are common in genotype B and C ETV resistance patients. Patients with virological breakthrough experienced more ETV resistance than non-complete virological group. There is no statistical difference in resistance between genotype B and C patients.
出处
《世界华人消化杂志》
CAS
北大核心
2009年第12期1260-1263,共4页
World Chinese Journal of Digestology
基金
首都特色临床医学技术发展研究研发攻关类基金资助项目
No.Z07050700690702~~
关键词
慢性乙型肝炎
恩替卡韦
耐药
基因型
Chronic hepatitis B
Entecavir
Drug resistance
Genotype
